Mind-body therapies like meditation, psychotherapy, and deep breathing may help reduce stress levels, potentially reducing ...
Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...
An allergic reaction in babies can range from mild to life-threatening. Here’s how to tell if your child is having an ...
Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...
Management of urticaria de pends on its cause ... for its antithrombotic properties can usually continue regular treatment. It is also good practice to recommend avoiding codeine and other ...
RBC Capital analyst Gregory Renza lowered the firm’s price target on Jasper Therapeutics (JSPR) to $48 from $68 and keeps an Outperform rating ...
Despite positive preliminary data from its early stage study of treating hives, Jasper Therapeutics Inc. saw its stock drop dramatically on Jan. 8. Results were from the ongoing phase Ib/IIa study of ...
Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.
A woman with a known nut allergy had a severe allergic reaction after sex, even though her partner bathed and brushed his ...